Evidence map›Paper›PMID 42542486›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Cysteine Re-bridging Using Divinyl Pyrimidine Reagents for the Generation of Antibody-Drug Conjugates.

Thomas Wharton, Sona Krajcovicova, David R Spring

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Thomas WhartonYusuf Hamied Department of Chemistry, Lensfield Road, Cambridge, CB2 1EW, UK.
Sona KrajcovicovaYusuf Hamied Department of Chemistry, Lensfield Road, Cambridge, CB2 1EW, UK.
David R SpringYusuf Hamied Department of Chemistry, Lensfield Road, Cambridge, CB2 1EW, UK. spring@ch.cam.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) are a powerful form of targeted therapy that can deliver drugs with a high level of selectivity towards a specific cell type, reducing off-target effects and increasing the therapeutic window compared to small-molecule therapeutics. However, creating ADCs that are stable, homogeneous, and with a controlled drug-to-antibody ratio (DAR) remains a significant challenge. Divinyl pyrimidine (DVP) reagents were developed as a method to irreversibly conjugate linker-payloads onto native antibodies to generate stable ADCs and antibody-probe systems with a precise drug-to-antibody ratio (DAR) of 4. This protocol describes how to conjugate DVPs to antibodies and methods for ADC characterization.

Indexed as

CysteineImmunoconjugatesPyrimidinesAntibodies, MonoclonalHumansAntibodies, MonoclonalCysteineImmunoconjugatesPyrimidinesAntibody characterizationAntibody-drug conjugatesCysteine conjugationDisulfide re-bridgingDrug-to-antibody ratio

Identifiers

PMID42542486

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.